<DOC>
	<DOC>NCT01266707</DOC>
	<brief_summary>The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.</brief_summary>
	<brief_title>Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma</brief_title>
	<detailed_description>It has been required to develop new treatment modalities for patients with advanced heptatocellular carcinoma. Immunotherapy is one of the encouraging modalities for patients. We have to assess its toxicities, clinical response and immune responsiveness.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Unresectable or treatmentresistant patients with Hepatocellular carcinoma Measurable disease by CT scan ECOG performance status 02 Life expectancy &gt; 3 months Laboratory values as follows: 2,000/mm3 &lt; WBC &lt;15,000/mm3, Platelet counts &gt; 75,000/mm3, Total Bilirubin &lt; 1.5 mg/dl, Asparate transaminase &lt; 150IU/L, Alanine transaminase &lt; 150 IU/L, Creatinine &lt; 3.0mg/dl HLAA*2402 Able and willing to give valid written informed consent Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception) Brestfeeder Active or uncontrolled infection Steroids or immunosuppressing agent dependent status Active or uncontrolled other malignancy Serious or uncured wound Decision of unsuitableness by principal investigator or physicianin charge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>peptide vaccine</keyword>
	<keyword>VEGFR</keyword>
</DOC>